Molnupiravir: A new candidate for COVID‐19 treatment

The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19. Antiviral medications are the candidate therapies for the management of COVID‐19. Molnup...

Descripción completa

Detalles Bibliográficos
Autores principales: Pourkarim, Fariba, Pourtaghi‐Anvarian, Samira, Rezaee, Haleh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929331/
https://www.ncbi.nlm.nih.gov/pubmed/34968008
http://dx.doi.org/10.1002/prp2.909
_version_ 1784670841814908928
author Pourkarim, Fariba
Pourtaghi‐Anvarian, Samira
Rezaee, Haleh
author_facet Pourkarim, Fariba
Pourtaghi‐Anvarian, Samira
Rezaee, Haleh
author_sort Pourkarim, Fariba
collection PubMed
description The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19. Antiviral medications are the candidate therapies for the management of COVID‐19. Molnupiravir is an antiviral drug with anti‐RNA polymerase activity and currently is under investigation for the treatment of patients with COVID‐19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID‐19 patients.
format Online
Article
Text
id pubmed-8929331
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89293312022-03-24 Molnupiravir: A new candidate for COVID‐19 treatment Pourkarim, Fariba Pourtaghi‐Anvarian, Samira Rezaee, Haleh Pharmacol Res Perspect Review Articles The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19. Antiviral medications are the candidate therapies for the management of COVID‐19. Molnupiravir is an antiviral drug with anti‐RNA polymerase activity and currently is under investigation for the treatment of patients with COVID‐19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID‐19 patients. John Wiley and Sons Inc. 2021-12-30 /pmc/articles/PMC8929331/ /pubmed/34968008 http://dx.doi.org/10.1002/prp2.909 Text en © 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Pourkarim, Fariba
Pourtaghi‐Anvarian, Samira
Rezaee, Haleh
Molnupiravir: A new candidate for COVID‐19 treatment
title Molnupiravir: A new candidate for COVID‐19 treatment
title_full Molnupiravir: A new candidate for COVID‐19 treatment
title_fullStr Molnupiravir: A new candidate for COVID‐19 treatment
title_full_unstemmed Molnupiravir: A new candidate for COVID‐19 treatment
title_short Molnupiravir: A new candidate for COVID‐19 treatment
title_sort molnupiravir: a new candidate for covid‐19 treatment
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929331/
https://www.ncbi.nlm.nih.gov/pubmed/34968008
http://dx.doi.org/10.1002/prp2.909
work_keys_str_mv AT pourkarimfariba molnupiraviranewcandidateforcovid19treatment
AT pourtaghianvariansamira molnupiraviranewcandidateforcovid19treatment
AT rezaeehaleh molnupiraviranewcandidateforcovid19treatment

Ejemplares similares